Stay updated with breaking news from Viral clearance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The country’s clinical trials seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug Ivermectin in asymptomatic and mild coronavirus disease (COVID-19) patients confined in isolation facilities will begin on Oct. 15, the Department of Science and Technology (DOS
The country’s eight month-long study on the use of anti-parasitic drug Ivermectin as a treatment for coronavirus disease (COVID-19) is set to begin on Sept. 15, the Department of Science and Technology (DOST) said Friday, Aug. 27.
(MANILA BULLETIN FILE PHOTO) DOST Undersecretary for Research a
Dengue virus infection is prevalent in tropical and sub-tropical regions of the world, which is fatal if untreated symptomatically. Emergence of new genotype within serotypes led to enhanced severity. The objective of the study is to identify the molecular characteristics of the DENV circulated during 2017 outbreak in Tamil Nadu, India and, to investigate the role of inflammatory cytokines in different ‘serotypes’ and in ‘dengue severity’. A total of 135 suspected samples were tested for DENV infection using IgM, IgG and qPCR assay; where 76 samples were positive for DENV and analysed for twelve inflammatory cytokines using ELISA. Serotyping shows 14 DENV-1, 22 DENV-2, 7 DENV-3 and 33 DENV-4, where DENV-4 was predominant. Among seventy-six, forty-two isolates were successfully sequenced for C-prM region and grouped. A lineage shift was observed in DENV-4 genotype. Irrespective of serotypes, IFNγ was significantly elevated than control and in primary infection indicating its role in immune response. GM-CSF and IP-10 was significantly elevated in secondary infection and, can be used as prognostic biomarker for secondary infection. Our observation shows differential cytokine expression profile varied with each serotype indicating serotype/genotype-specific viral proteins might play a major role in dengue severity. DENV-4 as dominant serotype was reported in Tamil Nadu for the first time during an outbreak with a mixed Th1/Th17 cytokine expression profile that correlated with disease severity. We conclude it is essential to identify circulating viral genotype and their fitness by mutational analysis to correlate with disease severity and immune status, as this correlation will be helpful in diagnostics and therapeutics applications.
Search jobs 03-Jun-2021 Global Viral Clearance Services Market 2021:COVID-19 Impact, Developments, and Regional Outlook,Demand,Forecast To 2028||Texcell, Merck KGaA, WuXi AppTec, Sartorius AG, Bioscience Laboratories, Eurofins Scientific, Syngene International Limited Latest released the research study on Global Viral Clearance Services Market, offers a detailed overview of the factors influencing the global business scope. Viral Clearance Services Market research report shows the latest market insights; current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Viral Clearance Services. The viral clearance services market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 1,563.74 million by 2028 and will grow at a CAGR of 18.88% in the above mentioned forecast period.
CHICAGO, May 27, 2021 /PRNewswire/ -- According to the new market research report "Single-use Assemblies Market by Product (Bag Assembly, Filtration Assembly, Bottle Assembly, Mixing Assembly)
As the final article in a three-part series that summarizes the discussions and exchanges of a BioPhorum Development Group workstream on small-scale...
Global Viral Clearance Market Statistics with Top 10 Key players in 2021 |Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy) – KSU ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting News provided by Share this article Share this article ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapy's 24 th Annual Meeting taking place from May 11 to 14, 2021, in virtual format. Presentations and posters will be available at https://www.asgct.org/. Oral presentations include: Abstract Title: Effects of Sexual Dimorphism and Genetic Background on AAV Tissue Transduction in Mice Following Intravenous Administration of a Diverse Capsid Pool (abstract #94)